Vendor, New York, NY
Glyphic Biotechnologies, Inc.
UEI F57WT7JZDH19, CAGE 94M19
1 award and $249,993 obligated between April 8, 2024 and April 8, 2024, 100% under full and open competition, against 2.0 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)NAICS 541715 | $249,993 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition After Exclusion of Sources | 1 |
| Small Business Set Aside - Total | 1 |
| Purchase Order | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| HT942524P0042Purchase Order, April 8, 2024, Full and Open Competition After Exclusion of Sources, 2 offers | Army Med Res Acq ActivityDefense Health Agency | Medical R and D Purchase Order for a DHA STTR Phase I, Proposal No. H23C-001-0042, Titled, "development of Anti-Glycan Antibodies Against MuNAICS 541715, PSC AN11 | $249,993 |
- Places of performance
- New York
- Product and service codes
- AN11 Health R&D Services; Health Care Services; Basic Research
- Transactions
- 1 across 1 awards